From March 28 to 31, the 27th Chinese Medical Doctor Association Interventional Cardiology Conference and the 13th China Chest Pain Center Conference were held in Guangzhou, Yangcheng. At the meeting, the first expert consensus on Tongluo drugs - "Chinese Expert Consensus on the Clinical Application of Tongxinluo in the Prevention and Treatment of Coronary Heart Disease" (hereinafter referred to as the "Consensus") - was formulated in strict accordance with international consensus standards (ESC Guidelines Evidence Classification and Recommendation Standards). release.
"Chinese Expert Consensus on the Clinical Application of Tongxinluo in the Prevention and Treatment of Coronary Heart Disease" press conference
The "Consensus" is guided by Professor Zhang Yun, academician of the Chinese Academy of Engineering and Qilu Hospital of Shandong University, and Professor Ge Junbo, academician of the Chinese Academy of Sciences and Zhongshan Hospital Affiliated to Fudan University. Professor Huo Yong from Peking University First Hospital, Professor Wu Zonggui from the Shanghai Institute of Integrated Traditional Chinese and Western Medicine for Cardiovascular Diseases, and Professor Lin Qian from Beijing University of Chinese Medicine Dongzhimen Hospital chaired the writing as members of the core expert group. More than 40 authoritative experts in the domestic cardiovascular field jointly Compiled with careful discussion.
The "Consensus" clarified 9 major categories of coronary heart disease-related populations involved in clinical practice and determined 22 outcome indicators. It aims to help physicians give full play to the clinical application value of Tongxinluo in people with coronary heart disease, optimize the prevention and treatment management plan of coronary heart disease by integrating traditional Chinese and Western medicine, minimize the risk of recurrence of cardiovascular events in patients, and improve their clinical outcomes.
Focusing on the treatment of coronary heart disease, the "Consensus" is released to guide clinical application
Cardiovascular disease is the main cause of death for urban and rural residents in my country. According to the "China Cardiovascular Health and Disease Report 2022", there are 11.39 million patients with coronary heart disease in my country, and the mortality rate from coronary heart disease is still showing a continuing upward trend; Patients with coronary heart disease in 2020 The total hospitalization cost is 116.959 billion yuan, and the average hospitalization cost per person is 14638.22 yuan, which has brought a heavy public health and economic burden to Chinese society.
Tongxinluo is a patented innovative drug developed under the guidance of the theory of collateral disease to treat ischemic cardiovascular and cerebrovascular diseases, diabetic microvascular disease and other diseases. It is a national medical insurance Class A product and a national essential drug list product. Over the past 20 years since its launch, Tongxinluo has been widely used in clinical practice and has been approved by more than 30 publications including the "Guidelines for the Rational Use of Drugs in Coronary Heart Disease", "China's Expert Consensus on the Diagnosis and Treatment of Multidisciplinary Microvascular Diseases", and "China's Guidelines for the Diagnosis and Treatment of Cerebral Infarction Integrated Traditional Chinese and Western Medicine". National cardiovascular and cerebrovascular disease guidelines/consensus recommendations, and its related scientific research and innovation achievements have won four national science and technology achievement awards.
Basic research shows that Tongxinluo has the effects of regulating lipids, anticoagulation, anti-inflammation, antioxidant, improving blood rheology, protecting vascular endothelium, and stabilizing plaque. A series of clinical studies have confirmed that the addition of Tongxinluo on the basis of standardized treatment can further benefit patients with coronary heart disease. In October 2023, the "Chinese Tongxinluo Myocardial Protection Study in the Treatment of Acute Myocardial Infarction (CTS-AMI)" led by Professor Yang Yuejin of Fuwai Hospital of the Chinese Academy of Medical Sciences was published in the international authoritative journal "JAMA". This is my country's first The results of the randomized controlled clinical trial study of traditional Chinese medicine published in the four top international medical journals are hailed as a major breakthrough in the integration of traditional Chinese and Western medicine in the cardiovascular field and are of landmark significance.
The content of this "Consensus" covers a variety of disease types and patient groups such as acute coronary syndrome, stable and unstable angina, and recommends the use of Tongxinluo in the treatment of different types of coronary heart disease. Tongxinluo has obtained 8 Class I recommendations and 9 Class A recommendations in terms of primary and secondary prevention and prevention and treatment of acute coronary syndrome (unstable angina pectoris, acute myocardial infarction). It is the first company to obtain this recommendation in acute coronary syndrome. Class I recommended innovative traditional Chinese medicine.
The "Consensus" clarifies 9 types of clinically involved coronary heart disease-related groups and determines 22 outcome indicators. In addition, the "Consensus" fully recorded the safety incidents of Tongxinluo and pointed out that Tongxinluo has good security. According to the National Adverse Drug Reaction Detection System, as of March 31, 2023, the reporting rate of Tongxinluo-related adverse reactions was within the very rare range (less than 2 in 10,000). The release of the "Consensus" will provide authoritative guidance to further clarify the applicable groups and the strength of evidence for Tongxinluo in the treatment of coronary heart disease, and better leverage the clinical application value of Tongxinluo in patients with coronary heart disease.
It is reported that the complete content of the "Consensus" will be published simultaneously in the "Chinese Journal of Cardiovascular Diseases (Online Edition)" and "Chinese Journal of Interventional Cardiology".
"Consensus" provides powerful weapons for the treatment of coronary heart disease
Academician of the Chinese Academy of Sciences, Professor Ge Junbo from Zhongshan Hospital Affiliated to Fudan University
Academician Ge Junbo pointed out that coronary heart disease is a major clinical health problem in my country and brings a heavy economic burden to society and families. Traditional Chinese medicine pays attention to the holistic view and has unique advantages in treating coronary heart disease. After more than 20 years of development, Tongxinluo has accumulated rich evidence-based medical evidence and provided a powerful weapon for clinical treatment of cardiovascular diseases. It is believed that the release of the "Consensus" can bring more standardized guidance to front-line clinicians and provide powerful treatment tools.
Professor Wu Zonggui, Shanghai Institute of Integrated Traditional Chinese and Western Medicine for Cardiovascular Diseases
Professor Wu Zonggui said that the release of the "Consensus" is a landmark moment in the field of coronary heart disease. The inheritance, innovation and development of traditional Chinese medicine have ushered in an unprecedented opportunity. As an innovative traditional Chinese medicine under the guidance of collateral disease theory, Tongxinluo has proven its efficacy and safety in treating coronary heart disease in numerous clinical studies and practices. This "Consensus" systematically summarizes the research progress of Tongxinluo in the field of coronary heart disease treatment. It not only represents researchers' understanding of Tongxinluo's prevention and treatment of coronary heart disease, but also reflects doctors' care for patients' health and quality of life.
Professor Huo Yong from Peking University First Hospital
Professor Huo Yong pointed out that this "Consensus" combines evidence-based evidence, expert opinions and empirical guidance, and is generated in accordance with a strict consensus-making process. He particularly emphasized that for different types of coronary heart disease, Tongxinluo can improve clinical outcomes and clinical symptoms based on standardized treatment, and improve the quality of life of patients with coronary heart disease.
Professor Lin Qian, Beijing University of Chinese Medicine Dongzhimen Hospital
Professor Lin Qian said that the formulation of this "Consensus" gathered many domestic authoritative experts in the fields of traditional Chinese medicine and Western medicine, adhering to the principle of being evidence-based, supplemented by consensus, and based on experience, and the entire process was rigorous and standardized. She expressed the hope that through the release of the "Consensus", it can provide help and guidance for clinicians to better apply Tongxinluo, and give full play to the advantages of integrating traditional Chinese and Western medicine and the clinical therapeutic value of Tongxinluo in patients with coronary heart disease. At the same time, we also look forward to more high-quality evidence-based research to provide clinical guidance in the future, and to further improve the health of the people through the integration of traditional Chinese and Western medicine.
"Traditional Chinese medicine is the representative of the motherland's culture that spans thousands of years. It is crucial to use scientific methods to explain the mechanism of traditional Chinese medicine clearly." Professor Li Xinli from the First Affiliated Hospital of Nanjing Medical University pointed out at the conclusion of the main report of the conference: "Over the years, traditional Chinese medicine has A number of studies conducted by Xinluo have proven its important role and unique advantages in the treatment of ischemic cardiovascular and cerebrovascular diseases. It can be said that Tongxinluo speaks clearly and clearly, with basic theory and clinical practice. There are also representative innovative traditional Chinese medicines with hard endpoint research results published in authoritative international journals. We hope that the publication of this "Consensus" can provide a demonstration effect for combined treatment and comprehensive management of coronary heart disease, and help build a healthy China. We look forward to more trends in traditional Chinese medicine in the future. world".